Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
15 p, 655.6 KB Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses / Xu, X. S. (Janssen Research & Development. LLC) ; Moreau, Philippe (CHU de Nantes) ; Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ; Lonial, S. (Winship Cancer Institute. Emory University) ; Jakubowiak, A. (University of Chicago Medical Center) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Krishnan, A. (City of Hope) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Luo, M. (Janssen Research & Development. LLC) ; Sun, Y. N. (Janssen Research & Development. LLC) ; Zhou, H. (Janssen Research & Development. LLC) ; Nnane, I. (Janssen Research & Development. LLC) ; Deraedt, W. (Janssen Research & Development) ; Qi, M. (Janssen Research & Development. LLC) ; Ukropec, J. (Janssen Scientific Affairs. LLC) ; Clemens, P. L. (Janssen Research & Development. LLC) ; Universitat Autònoma de Barcelona
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7. [...]
2020 - 10.1007/s12325-020-01247-8
Advances in Therapy, Vol. 37 Núm. 4 (january 2020) , p. 1464-1478  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.